Related Experiment Video

Updated: Dec 27, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

971

Mechanisms of Resistance to PD-1 Checkpoint Blockade

Justin C Moser1, Siwen Hu-Lieskovan2

  • 1HonorHealth Research Institute, Scottsdale, AZ, USA.

Drugs
|February 26, 2020
PubMed

Insights

Immune checkpoint inhibitors (ICIs) offer durable responses in many cancers, but resistance limits efficacy. Understanding resistance mechanisms is crucial for developing personalized strategies to improve patient outcomes with these immunotherapies.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Therapy

Background:

  • Immune checkpoint inhibitors (ICIs), targeting CTLA-4, PD-1, or PD-L1, have transformed cancer treatment.
  • ICIs are approved for multiple cancer types, offering durable responses in some patients.
  • However, a significant proportion of patients do not respond to ICIs, and some responders relapse.

Purpose of the Study:

  • To review the mechanisms of resistance to immune checkpoint inhibitors (ICIs).
  • To discuss potential strategies for overcoming ICI resistance.
  • To highlight the need for patient-specific approaches to improve ICI efficacy.

Main Methods:

  • Literature review of defined mechanisms of resistance to ICIs.
  • Analysis of current understanding of ICI resistance pathways.
  • Discussion of potential therapeutic strategies to overcome resistance.

Main Results:

  • Multiple mechanisms contribute to primary and acquired resistance to ICIs.
  • Understanding these diverse resistance mechanisms is critical for improving treatment outcomes.
  • Patient-specific strategies are likely necessary to effectively reverse ICI resistance.

Conclusions:

  • Resistance to ICIs remains a major challenge in cancer therapy.
  • Further research into resistance mechanisms is essential for developing novel therapeutic approaches.
  • Personalized medicine strategies hold promise for overcoming ICI resistance and improving patient survival.

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.1K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.1K